Gene information
The Riskguard® test gene information
Browse the resources below to learn more about each gene the test evaluates. Please discuss your Riskguard test results with a healthcare provider.
The Riskguard test checks genes across 11 cancer types
Approximately 1 in 8 cancers are due to a hereditary syndrome.1 The Riskguard test evaluates 59 different genes, so patients can learn more about their genetic risk for some of the most common and aggressive cancer types.
Learn more about the genes we evaluate
The Riskguard test can give you powerful information about your hereditary risk for cancer. Patients with a family history of cancer can gain insights into their options to reduce risk, as well as screening recommendations. Patients already diagnosed with cancer can learn how their results could inform treatment or screening.
A negative result means you’ll have powerful information
Negative results could mean less frequent screenings and avoiding unnecessary treatment.2-4 Patients and providers can use this information, along with family history and other factors, to decide next steps.
A positive result does not mean you’ll develop cancer
A positive result does not mean a patient will develop cancer; it means they may be at a higher risk than average. We’re here to support patients and providers as you create a personalized prevention or treatment plan.
An uncertain result means there’s not enough data
An uncertain result means there isn't enough data available to determine whether a gene change increases cancer risk or not. As new research is conducted, more information could be made available.
Individual gene information
Download information on each gene the Riskguard test checks. Learn what a positive result could mean, see recommendations for monitoring and surveillance, and learn how the results could impact family members.
A - C
APC
ATM
AXIN2
BAP1
BARD1
BMPR1A
BRCA1
BRCA2
BRIP1
CDH1
CDK4
CDKN1B
CDKN2A
CHEK2
CTNNA1
D - F
DICER1
EGFR
EPCAM
FH
FLCN
G - L
GREM1
HOXB13
KIT
M - O
MAX
MBD4
MEN1
MET
MITF
MLH1
MSH2
MSH6
MUTYH
NF1
NTHL1
P - R
PALB2
PDGFRA
PMS2
POLD1
POLE
POT1
PTCH1
PTEN
RAD51C
RAD51D
RET
S - T
SDHA
SDHAF2
SDHB
SDHC
SDHD
SMAD4
SMARCA4
STK11
TMEM127
TP53
TSC1
TSC2
U - Z
VHL
We're here for you
With questions about ordering the Riskguard test, insurance billing and payment options, checking results, or getting connected with a genetic counselor, call us at +1 866-662-6897 or email us at riskguard@exactsciences.com .
References and footnotes
- DeBortoli E, McGahan E, Yanes T, et al., Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer, Cancer Med 2025;14(15):e71080.
- Robson M, Seock-Ah I, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017;377:523-533.
- Tischler J, Crew KD, Chung WK. The role of tumor and germline genetic testing in breast cancer management. Ann Intern Med 2019;171(12):925-930.
- Kurian AW, Ward KC, Abrahamse P, et al. Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. JAMA Oncol 2020;6(4):e196400.
The Exact Sciences Riskguard test was developed, and its performance characteristics validated by an Exact Sciences laboratory following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The test is performed in Marshfield, WI at PreventionGenetics LLC, a wholly owned subsidiary of Exact Sciences. PreventionGenetics is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. It has not been cleared or approved by the US Food and Drug Administration or other notified regulatory authority. Genomic Health, Inc., an Exact Sciences company, is the billing entity for the Riskguard test.